Even better, vaccines are being developed by multiple companies.
Healthcare professionals are hopeful this drug can persuade those not yet vaccinated to receive the medication — because it uses a more traditional method to protect patients from the virus.
There are also clotting concerns with the , which is also an adenovirus-vector-based vaccine, after six women developed the condition in the United States out of 6.